Open AccessJournal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
Reads0
Chats0
TLDR
The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.Abstract:
One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising approach to treating cancers, has been the identification of a biologically active dose rather than a maximum tolerated dose. The goal of the present study was to identify a pharmacokinetic/pharmacodynamic relationship in preclinical models that could be used to help guide selection of a clinical dose. SU11248, a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, was used as the pharmacological agent in these studies. In mouse xenograft models, SU11248 exhibited broad and potent antitumor activity causing regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines. To predict the target SU11248 exposure required to achieve antitumor activity in mouse xenograft models, we directly measured target phosphorylation in tumor xenografts before and after SU11248 treatment and correlated this with plasma inhibitor levels. In target modulation studies in vivo , SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor β phosphorylation (in a time- and dose-dependent manner) when plasma concentrations of inhibitor reached or exceeded 50–100 ng/ml. Similar results were obtained in a functional assay of VEGF-induced vascular permeability in vivo . Constant inhibition of VEGFR2 and PDGF receptor β phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 h of a 24-h dosing interval. The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.read more
Citations
More filters
Journal ArticleDOI
Novel treatments for metastatic renal cell carcinoma.
TL;DR: Recent new insights in the molecular biology of clear RCC has revealed a key-role for vascular endothelial growth factor (VEGF) in the stimulation of angiogenesis in this highly vascularized tumour, which opens interesting new treatment strategies including blockage of VEGF with the monoclonal antibody bevacizumab and inhibition of V EGF receptor tyrosine kinases.
Journal ArticleDOI
Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
Anne-Marie Egert-Schmidt,Jan Dreher,Ute Dunkel,Simone Kohfeld,Lutz Preu,Holger Weber,Jan E. Ehlert,Bettina Mutschler,Frank Totzke,Christoph Schächtele,Michael H.G. Kubbutat,Knut Baumann,Conrad Kunick +12 more
TL;DR: To develop multikinase inhibitors with dual PLK1/VEGF-R2 inhibitory activity, the d-annulated 1-benzazepin-2-one scaffold present in the paullone family of kinase inhibitors was investigated as a general structure template suitable for anchoring annulated heterocycles at the hinge region of the ATP binding site.
Journal ArticleDOI
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib
Nienke A G Lankheet,Ingrid M.E. Desar,Sasja F. Mulder,David M. Burger,D. M. Kweekel,Carla M.L. van Herpen,Winette T. A. van der Graaf,Winette T. A. van der Graaf,Nielka P. van Erp +8 more
TL;DR: Dose optimization proved an effective tool to reach adequate trough levels in patients treated with imatinib, sunitinib and pazopanib andTherapeutic drug monitoring may add to the improvement of efficacy and reduction of toxicity and costs of these treatments.
Journal ArticleDOI
Bioluminescence imaging in vivo - application to cancer research.
Ariane Söling,Nikolai G. Rainov +1 more
TL;DR: The application of non-invasive bioluminescence imaging to cancer research in general and to the area of experimental neuro-oncology in particular is discussed.
Journal ArticleDOI
Prognostic significance of angiogenesis in gastrointestinal stromal tumor
Masakazu Imamura,Hidetaka Yamamoto,Norimoto Nakamura,Yoshinao Oda,Takashi Yao,Yoshihiro Kakeji,Hideo Baba,Yoshihiko Maehara,Masazumi Tsuneyoshi +8 more
TL;DR: The results suggest that the evaluation of MVD and V EGF expression is useful for predicting the aggressive biologic behavior of GIST, and that angiogenesis associated with VEGF may play an important role, at least in part, in the progression of Gist.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Cell signaling by receptor-tyrosine kinases
TL;DR: Understanding of the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.
Journal ArticleDOI
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
TL;DR: It is shown that expression of an endothelial cell-specific mitogen, vascular endothelial growth factor (VEGF), is induced in astrocytoma cells but is dramatically upregulated in two apparently different subsets of glioblastoma cells, which strongly support the concept that tumour angiogenesis is regulated by paracrine mechanisms and identify VEGF as a potential tumourAngiogenesis factor in vivo.
Journal ArticleDOI
Signaling by Receptor Tyrosine Kinases
TL;DR: The epidermal growth factor receptor (EGFR) is one member of the ERBB family of transmembrane gly-coprotein tyrosine receptor kinases (RTK) and stimulates intracellular signal transduction cascades that are involved in regulating cellular proliferation, differentiation, and survival.
Journal ArticleDOI
Molecular and biological properties of vascular endothelial growth factor.
TL;DR: Current evidence indicates that VEGF is essential for embryonic vasculogenesis and angiogenesis, and both therapeuticAngiogenesis using recombinant V EGF or VEGFs gene transfer and inhibition of VEGf-mediated pathological angiogenic are being pursued.
Related Papers (5)
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott Wilhelm,Christopher A. Carter,LiYa Tang,Dean Wilkie,Angela McNabola,Hong Rong,Charles Chen,Xiaomei Zhang,Patrick Vincent,Mark McHugh,Yichen Cao,Jaleel Shujath,Susan Gawlak,Deepa Eveleigh,Bruce Rowley,Li Liu,Lila Adnane,Mark Lynch,Daniel Auclair,Ian W. Taylor,Rich Gedrich,Andrei Voznesensky,Bernd Riedl,Leonard Post,Gideon Bollag,Pamela A. Trail +25 more